Article: Nicotinamide Riboside Restores Mitochondrial Function in Alzheimer's Disease: Preclinical Findings

PrevNext
Alzheimer's Disease Neurological Health Preclinical

Nicotinamide Riboside Restores Mitochondrial Function in Alzheimer's Disease: Preclinical Findings

Synopsis

Mutant APP and amyloid-β (Aβ) disrupt mitochondrial dynamics and damage synapses in Alzheimer’s disease (AD), partly due to impaired mitophagy, the removal of dysfunctional mitochondria. Using mAPP-transfected HT22 hippocampal neurons, this study tested four mitophagy enhancers—urolithin A (UA), actinonin, tomatidine, and nicotinamide riboside (NR). mAPP expression caused excessive mitochondrial fission, reduced fusion, impaired respiration, synaptic gene loss, and poor cell survival. All four enhancers reversed these defects by improving mitochondrial morphology, boosting mitophagy and fusion-related genes, restoring synaptic markers, and enhancing respiration and viability. UA showed the strongest overall effect, but NR also contributed meaningful restoration of mitochondrial and synaptic function. These results highlight mitophagy enhancement as a promising therapeutic strategy for Alzheimer’s disease.

Journal

Mitochondrion

Share

Read more

Cellular Health

Nicotinamide Riboside and NMN Boost NAD+ Through Microbiota Conversion: Preclinical Findings

Synopsis Using NAD+ metabolomics in mice, this study found that nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are not directly absorbed intact in large amounts. Instead, most or...

Read more
Healthy Aging & Longevity

Nicotinamide Riboside Improves Mitochondrial Health in Werner Syndrome: Preclinical Findings

SynopsisWerner syndrome (WS) is a rare accelerated aging disease caused by mutations in the WRN gene, leading to metabolic problems and premature cell aging. This study found that loss of WRN incre...

Read more